Stockscreener 앱 받기
2.27
0.44%
0.01
전일 마감가:
$2.26
열려 있는:
$2.2
하루 거래량:
3,870
Relative Volume:
0.10
시가총액:
$34.14M
수익:
-
순이익/손실:
$-16.26M
주가수익비율:
-1.9214
EPS:
-1.1814
순현금흐름:
$-13.50M
1주 성능:
+1.79%
1개월 성능:
-1.30%
6개월 성능:
-46.59%
1년 성능:
-37.31%
1일 변동 폭
$2.15
$2.29
1주일 범위
$2.04
$2.3999
52주 변동 폭
$1.50
$5.94
인텐시티 테라퓨틱스 Stock (INTS) Company Profile
명칭
Intensity Therapeutics Inc
전화
203-221-7381
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
INTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
2.27 | 34.14M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.99 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.20 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.43 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.36 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
269.53 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스
Equillium (NASDAQ:EQ) Stock Quotes, Forecast and News Summary - Benzinga
Intensity Infrastucture Partners Launches Open Season for New Natural Gas Transmission Pipeline to Serve the Bakken Region - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
Drug Monitoring Committee Authorizes Continuation of Intensity T - GuruFocus.com
Intensity Therapeutics' sarcoma trial proceeds after review By Investing.com - Investing.com Canada
Intensity Therapeutics' sarcoma trial proceeds after review - Investing.com India
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review - Nasdaq
High Intensity Focused Ultrasound Market Forecast and Company Analysis 2025-2033 Featuring Koninklijke Philips, Johnson & Johnson, Hitachi, General Electrics, Medtronic, Stryker, EDAP TMS, Theraclion - Yahoo Finance
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Soft Tissue Sarcoma Market Poised for Significant Growth from - openPR
Soft Tissue Sarcoma Pipeline Review 2024: Clinical Trials - openPR
Alliance Global Partners Initiates Coverage of Intensity Therapeutics (INTS) with Buy Recommendation - MSN
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 - PR Newswire
Avoiding Isolation By Volunteering Offers Mental Health Benefits to Seniors - 69News WFMZ-TV
Retrospective Analysis of Dosimetric Comparison Between Intensity-Modulated Radiation Therapy and Volumetric-Modulated Arc Therapy in Patients With Esophageal Cancer - Cureus
Intensity Therapeutics stock hits 52-week low at $1.73 By Investing.com - Investing.com Australia
Intensity Therapeutics stock hits 52-week low at $1.73 - Investing.com
Internal Radiation Therapy - Market.us
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
Myelodysplastic Syndrome (MDS) Drugs Market Trends and Sales Forecast to 2030: Total Revenues to Reach US$4.1 Billion Worldwide, with Immunomodulatory Drugs Dominating Shares - GlobeNewswire
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 By Investing.com - Investing.com Australia
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 - Investing.com
Top pharma biotech companies R&D intensity globally 2023 - Statista
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List - Yahoo Finance
Intensity Therapeutics reports positive results of INT230-6 in breast cancer - Yahoo Finance
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - Insider Monkey
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - Yahoo Finance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Brea - Yahoo Finance
인텐시티 테라퓨틱스 (INTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.83%
0.59%
자본화:
|
볼륨(24시간):